These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11967798)

  • 1. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
    Park JB; Intengan HD; Schiffrin EL
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
    Schiffrin EL; Park JB; Intengan HD; Touyz RM
    Circulation; 2000 Apr; 101(14):1653-9. PubMed ID: 10758046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospective study of the effects of an angiotensin converting enzyme inhibitor and a beta blockader on the structure and function of resistant arteries in mild essential hypertension].
    Schiffrin EL; Deng LY; Larochelle P
    Arch Mal Coeur Vaiss; 1994 Aug; 87(8):979-81. PubMed ID: 7755476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antihypertensive treatment on small artery remodeling in hypertension.
    Schiffrin EL
    Can J Physiol Pharmacol; 2003 Feb; 81(2):168-76. PubMed ID: 12710531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
    Schiffrin EL; Deng LY; Larochelle P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S51-6. PubMed ID: 7700067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
    Savoia C; Touyz RM; Amiri F; Schiffrin EL
    Hypertension; 2008 Feb; 51(2):432-9. PubMed ID: 18195160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    Schiffrin EL
    Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
    Sabino B; Lessa MA; Nascimento AR; Rodrigues CA; Henriques Md; Garzoni LR; Levy BI; Tibiriçá E
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):402-9. PubMed ID: 18427284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of losartan and atenolol on memory function in very elderly hypertensive patients.
    Fogari R; Mugellini A; Zoppi A; Derosa G; Pasotti C; Fogari E; Preti P
    J Hum Hypertens; 2003 Nov; 17(11):781-5. PubMed ID: 14578918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
    Garcia R; Bonhomme MC; Diebold S
    J Hypertens; 1996 Jan; 14(1):81-9. PubMed ID: 12013499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
    Nashar K; Nguyen JP; Jesri A; Morrow JD; Egan BM
    Am J Hypertens; 2004 Jun; 17(6):477-82. PubMed ID: 15177518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of losartan in female and male spontaneously hypertensive rats.
    de P Rodrigues SF; dos Santos RA; Silva-Antonialli MM; Scavone C; Nigro D; Carvalho MH; de Cássia Tostes R; Fortes ZB
    Life Sci; 2006 Apr; 78(19):2280-5. PubMed ID: 16337658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.